Differences in Arrhythmic Risk in Nocturnal, Daytime Hypoglycemia

Share this content:
Differences in Arrhythmic Risk in Nocturnal, Daytime Hypoglycemia
Differences in Arrhythmic Risk in Nocturnal, Daytime Hypoglycemia

TUESDAY, Feb. 28, 2017 (HealthDay News) -- For young adults with type 1 diabetes, there are differences in arrhythmic risk and cardiac repolarization during nocturnal versus daytime hypoglycemia, according to a study published online Feb. 17 in Diabetes Care.

Peter Novodvorsky, from the University of Sheffield in the United Kingdom, and colleagues examined the effect of nocturnal and daytime clinical hypoglycemia on electrocardiogram (ECG) in 37 individuals with type 1 diabetes. Participants underwent 96 hours of simultaneous ambulatory ECG and blinded continuous interstitial glucose monitoring (CGM).

The researchers obtained 2,395 hours of simultaneous ECG and CGM recordings: 159 and 1,355 hours were designated hypoglycemia and euglycemia. The median duration of hypoglycemia was longer during the night than during the daytime (60 versus 44 minutes; P = 0.020). Overall, 24.1 and 51.0 percent of nocturnal and daytime episodes, respectively, were symptomatic. Compared with matched euglycemia, bradycardia was more frequent during nocturnal hypoglycemia (incidence rate ratio [IRR], 6.44; 95 percent confidence interval [CI], 6.26 to 6.66; P < 0.001). Bradycardia was less frequent during daytime hypoglycemia (IRR, 0.023; 95 percent CI, 0.002 to 0.26; P = 0.002), while atrial ectopics were more frequent (IRR, 2.29; 95 percent CI, 1.19 to 4.39; P = 0.013). During nocturnal and daytime hypoglycemia there was prolonged QTc, T-peak to T-end interval duration, and decreased T-wave symmetry.

"Our data provide further evidence that hypoglycemia is proarrhythmogenic," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »